Design
Review
Authors
Loading...
Chymase inhibition should not yet alter practice; leaves open complementary targeting beyond ACE in cardiovascular disease.
Key points are not available for this paper at this time.
Dell’Italia et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: